Jesus F San Miguel

Jesus F San Miguel

UNVERIFIED PROFILE

Are you Jesus F San Miguel?   Register this Author

Register author
Jesus F San Miguel

Jesus F San Miguel

Publications by authors named "Jesus F San Miguel"

Are you Jesus F San Miguel?   Register this Author

100Publications

5299Reads

33Profile Views

The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma.

Clin Cancer Res 2019 May 28;25(10):3176-3187. Epub 2019 Jan 28.

Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369 and CB16/12/00489, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-1597DOI Listing
May 2019

How deep is the myeloma iceberg?

Blood 2018 12;132(23):2424-2425

Clinica Universidad de Navarra.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-10-878637DOI Listing
December 2018

Management of multiple myeloma in the newly diagnosed patient.

Hematology Am Soc Hematol Educ Program 2017 12;2017(1):498-507

Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Navarra, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2017.1.498DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6142596PMC
December 2017

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.

J Clin Oncol 2017 Sep 12;35(25):2900-2910. Epub 2017 May 12.

Juan-Jose Lahuerta, Maria-Teresa Cedena, Joaquin Martinez-Lopez, and María-Luisa Martín-Ramos, Hospital 12 de Octubre, CIBERONC; Raquel de Paz, Hospital Universitario La Paz; Rafael Martinez, Hospital Clínico San Carlos; Adrian Alegre, Hospital Universitario La Princesa, Madrid; Bruno Paiva and Jesus F. San-Miguel, Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona; Laura Rosiñol, and Joan Blade, Hospital Clínic de Barcelona, Barcelona; Maria-Belen Vidriales, Noemi Puig, Norma C. Gutierrez, Alejandro Martin, and María-Victoria Mateos, Hospital Universitario de Salamanca Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBERONC; Alberto Orfao, Servicio General de Citometría-NUCLEOS, Centro de Investigación del Cancer (IBMCC-USAL, CSIC), IBSAL and Department of Medicine, Universidad de Salamanca, CIBERONC, Salamanca; Lourdes Cordón and Javier De la Rubia, Hospital Universitario y Politécnico La Fe; Ana-Isabel Teruel, Hospital Clínico de Valencia, Valencia; Albert Oriol, Hospital Germans Trias i Pujol, Badalona; María-Asunción Echeveste, Hospital de Donostia, San Sebastian; Felipe de Arriba, Hospital Morales Meseguer, Murcia; Miguel T. Hernandez, Hospital Universitario de Canarias, Tenerife; Luis Palomera, Hospital Universitario Lozano Blesa, Zaragoza, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.2517DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568033PMC
September 2017

Multiple Myeloma Minimal Residual Disease.

Cancer Treat Res 2016;169:103-122

Centro de Investigacion Medica Aplicada (CIMA), Clinica Universidad de Navarra, IDISNA, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-40320-5_7DOI Listing
June 2017

Deacetylase inhibitors: an advance in myeloma therapy?

Expert Rev Hematol 2017 Mar 1;10(3):229-237. Epub 2017 Feb 1.

a Department of Hematologic Malignancies , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2017.1280388DOI Listing
March 2017

Is immunotherapy here to stay in multiple myeloma?

Haematologica 2017 03 12;102(3):423-432. Epub 2017 Jan 12.

Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2016.152504DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394971PMC
March 2017

Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.

J Clin Oncol 2016 11;34(32):3921-3930

A. Keith Stewart, Mayo Clinic, Scottsdale, AZ; Meletios A. Dimopoulos, Alexandra Hospital, Athens, Greece; Tamás Masszi, St. István and St. László Hospital, Semmelweis University, Budapest, Hungary; Ivan Špička, General University Hospital in Prague, Prague; Roman Hájek, University Hospital Brno and University of Ostrava, Brno, Czech Republic; Albert Oriol, Institut Català d'Oncologia, Institut Josep Carreras, Hospital Germans Trias i Pujol; Laura Rosiñol, Hospital Clínic de Barcelona, Barcelona; Jesus F. San-Miguel, Clinica Universidad de Navarra/El Centro de Investigacíon Médica Aplicada, Instituto de Investigacíon Sanitaria de Navarra, Pamplona, Spain; David S. Siegel, John Theurer Cancer Center at Hackensack University, Hackensack, NJ; Ruben Niesvizky, Weill Cornell Medical College, New York, NY; Andrzej J. Jakubowiak, University of Chicago Medicine, Chicago, IL; Heinz Ludwig, Wilhelminen Cancer Research Institute, Wilheminenspital, Vienna, Austria; Jacqui Buchanan, Xinqun Yang, Biao Xing, Naseem Zojwalla, and Margaret Tonda, Onyx Pharmaceuticals, South San Francisco, CA; Kim Cocks, KCStats Consultancy, Leeds, United Kingdom; Philippe Moreau, University of Nantes, Nantes, France; and Antonio Palumbo, University of Torino, Torino, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.9648DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791840PMC
November 2016

Utility of flow cytometry studies in the management of patients with multiple myeloma.

Curr Opin Oncol 2016 11;28(6):511-517

Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000331DOI Listing
November 2016

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.

Clin Cancer Res 2016 Aug 22;22(16):4206-4214. Epub 2016 Mar 22.

Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, and Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-2793DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4987182PMC
August 2016

Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.

Expert Rev Clin Pharmacol 2016 26;9(1):35-48. Epub 2015 Oct 26.

d CIMA, IDISNA , Clínica Universidad de Navarra , Pamplona , Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17512433.2016.1096773DOI Listing
June 2016

The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.

Future Oncol 2015 ;11(8):1153-68

Division of Hematologic Malignancy, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.15.9DOI Listing
February 2016

Smoldering multiple myeloma: when to observe and when to treat?

Am Soc Clin Oncol Educ Book 2015 :e484-92

From the University Hospital of Salamanca/IBSAL, Salamanca, Spain; Clínica Universidad de Navarra/CIMA, Navarra, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e484DOI Listing
February 2016

Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma.

Clin Cancer Res 2016 Jan 4;22(1):207-17. Epub 2015 Sep 4.

Centro de Investigacion del Cancer-IBMCC (USAL-CSIC), Salamanca, Spain. Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain. Servicio de Hematología, Hospital Universitario, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2796DOI Listing
January 2016

Treatment for patients with newly diagnosed multiple myeloma in 2015.

Blood Rev 2015 Nov 12;29(6):387-403. Epub 2015 Jun 12.

Clínica Universidad de Navarra/Centro de Investigación Médica Aplicada (CIMA), Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.blre.2015.06.001DOI Listing
November 2015

Panobinostat for the Treatment of Multiple Myeloma.

Clin Cancer Res 2015 Nov 11;21(21):4767-73. Epub 2015 Sep 11.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0530DOI Listing
November 2015

Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells.

Cancer Cell 2015 Sep;28(3):281-3

Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), IDISNA, 31008 Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2015.08.009DOI Listing
September 2015

Authors' Response.

Am J Hematol 2015 Aug;90(8):E146

Centro Investigación Medica Aplicada, Clinica Universidad De Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.24079DOI Listing
August 2015

Guidelines for determination of the number of prior lines of therapy in multiple myeloma.

Blood 2015 Aug;126(7):921-2

Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-05-647636DOI Listing
August 2015

Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?

Clin Cancer Res 2015 May 9;21(9):2001-8. Epub 2015 Mar 9.

Clinica Universidad de Navarra, CIMA, IDISNA, Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2841DOI Listing
May 2015

Introduction to a series of reviews on multiple myeloma.

Blood 2015 May 2;125(20):3039-40. Epub 2015 Apr 2.

Associate Editor.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2015-01-61
Publisher Site
http://dx.doi.org/10.1182/blood-2015-01-613596DOI Listing
May 2015

Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma.

Biochim Biophys Acta 2015 Mar 11;1849(3):353-66. Epub 2014 Dec 11.

Servicio de Hematología, Hospital Universitario, IBSAL, IBMCC (USAL-CSIC), Salamanca, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbagrm.2014.12.002DOI Listing
March 2015

Multiple myeloma and chronic leukaemias in 2014: improved understanding of disease biology and treatment.

Nat Rev Clin Oncol 2015 Feb 16;12(2):71-2. Epub 2014 Dec 16.

MD Anderson Cancer Center, University of Texas, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrclinonc.2014.216
Publisher Site
http://dx.doi.org/10.1038/nrclinonc.2014.216DOI Listing
February 2015

Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.

Oncotarget 2014 Sep;5(18):8284-305

Centro de Investigación del Cáncer, IBMCC (Universidad de Salamanca-CSIC), Salamanca, Spain. Hospital Universitario de Salamanca-IBSAL, Salamanca, Spain. Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226683PMC
http://dx.doi.org/10.18632/oncotarget.2058DOI Listing
September 2014

NADPH oxidases as therapeutic targets in chronic myelogenous leukemia.

Clin Cancer Res 2014 Aug 15;20(15):4014-25. Epub 2014 May 15.

Department of Biochemistry and Molecular Biology, University of Salamanca; Instituto de Investigación Biomédica de Salamanca (IBSAL);

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-3044DOI Listing
August 2014

How should we treat newly diagnosed multiple myeloma patients?

Hematology Am Soc Hematol Educ Program 2013 ;2013:488-95

1Hospital Universitario de Salamanca and.

View Article

Download full-text PDF

Source
http://www.asheducationbook.org/cgi/doi/10.1182/asheducation
Publisher Site
http://dx.doi.org/10.1182/asheducation-2013.1.488DOI Listing
July 2014

Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeutics.

World J Stem Cells 2014 Jul;6(3):322-43

Antonio Garcia-Gomez, Fermin Sanchez-Guijo, Jesus F San Miguel, Mercedes Garayoa, Cancer Research Center, IBMCC (University of Salamanca-CSIC), 37007 Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4252/wjsc.v6.i3.322DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4131274PMC
July 2014

Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease.

Clin Cancer Res 2014 Mar 31;20(6):1542-54. Epub 2014 Jan 31.

Authors' Affiliations: Centro de Investigación del Cáncer, IBMCC (Universidad de Salamanca-CSIC); Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León; Hospital Universitario de Salamanca-IBSAL, Salamanca; Laboratorio de Imagen del Cáncer, Centro de Investigación Médica Aplicada, Universidad de Navarra, Pamplona, Spain; MGH Cancer Center, Massachusetts General Hospital; Dana-Farber Cancer Institute, Harvard Medical School, Boston; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA; and Departments of Cell Biology and Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-1657DOI Listing
March 2014

Initial treatment of transplant-ineligible patients in multiple myeloma.

Expert Rev Hematol 2014 Feb 28;7(1):67-77. Epub 2013 Nov 28.

Hospital Universitario de Salamanca, Paseo San Vicente 58-182, 37007 Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2014.864230DOI Listing
February 2014

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.

J Clin Oncol 2014 Feb 13;32(6):587-600. Epub 2014 Jan 13.

Antonio Palumbo and Alessandra Larocca, University of Torino, Torino; Michele Cavo, Seràgnoli Institute of Hematology, Bologna University School of Medicine, Bologna, Italy; S. Vincent Rajkumar, Mayo Clinic, Rochester, MN; Jesus F. San Miguel, University Hospital of Salamanca, Salamanca, Spain; Ruben Niesvizky, Weill Cornell Medical College, New York, NY; Gareth Morgan, Royal Marsden Hospital, London, United Kingdom; Ola Landgren, National Cancer Institute, Bethesda, MD; Roman Hajek, University of Ostrava School of Medicine and University Hospital Ostrava, Ostrava, Czech Republic; Hermann Einsele, University of Wurzburg, Wurzburg, Germany; Kenneth C. Anderson and Paul G. Richardson, Dana-Farber Cancer Institute, Boston, MA; Meletios A. Dimopoulos, University of Athens School of Medicine, Athens, Greece; Andrew Spencer, Alfred Hospital, Melbourne, Victoria, Australia; A. Keith Stewart, Mayo Clinic, Scottsdale, AZ; Kazuyuki Shimizu, Aichi Gakuin Hospital, Nagoya, Japan; Sagar Lonial, Emory University, Atlanta, GA; Pieter Sonneveld, Erasmus Medical Centre, Rotterdam, the Netherlands; Brian G.M. Durie, Cedars-Sinai Comprehensive Cancer Center, Los Angeles, CA; Philippe Moreau, University Hospital, Nantes, France; and Robert Z. Orlowski, MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/32/6/587.full.pdf
Web Search
https://myeloma.org/pdfs/IMWG_Pub/2014%20JCO-%20Palumbo-%20I
Web Search
http://szpiczak.org/lang/aktualnosci/publikacje/rok_2013/LUD
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.48.7934
Publisher Site
http://dx.doi.org/10.1200/JCO.2013.48.7934DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3918540PMC
February 2014

New approaches to smoldering myeloma.

Curr Hematol Malig Rep 2013 Dec;8(4):270-6

Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca-Consejo Superior de Investigaciones Científicas, Salamanca, Spain,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-013-0174-1DOI Listing
December 2013

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

J Clin Oncol 2013 Oct 9;31(29):3696-703. Epub 2013 Sep 9.

Jesús F. San-Miguel and María Victoria Mateos, Servicio e Hematologia, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Institut de Bilogia Molecular de Barcelona (Universidad de Salamanca-Spanish National Research Council), Salamanca; Joan Bladé, Hospital Clinic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain; Paul G. Richardson and Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA; David Siegel, Hackensack University Medical Center, Hackensack; Kaushal K. Mishra and Song Mu, Novartis Pharmaceuticals Corporation, East Hanover, NJ; Andreas Günther, University of Kiel, Kiel; Orhan Sezer, Charité Universitätsmedizin Berlin, Berlin, Germany; Richard LeBlanc, Maisonneuve-Rosemont Hospital, Montreal, Quebec; Heather Sutherland, Vancouver General Hospital, Vancouver, British Columbia, Canada; and Monika Sopala and Priscille M. Bourquelot, Novartis Pharma AG, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2012.46.7068DOI Listing
October 2013

Novel generation of agents with proven clinical activity in multiple myeloma.

Semin Oncol 2013 Oct;40(5):618-33

Haematology Department, University Hospital of Salamanca, Cancer Research Center (IBMCC-CSIC), University of Salamanca, Institute of Biomedical Research of Salamanca (IBSAL), Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2013.07.005DOI Listing
October 2013

Treatment for high-risk smoldering myeloma.

N Engl J Med 2013 10;369(18):1764-5

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1310911DOI Listing
October 2013

Multiple myeloma patients have a specific serum metabolomic profile that changes after achieving complete remission.

Clin Cancer Res 2013 Sep 19;19(17):4770-9. Epub 2013 Jul 19.

Structural Biochemistry Laboratory, Centro de Investigación Príncipe Felipe, Valencia, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-2917DOI Listing
September 2013

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

N Engl J Med 2013 Aug;369(5):438-47

Hospital Universitario de Salamanca, Instituto de Biología Molecular y Celular del Cáncer, Universidad de Salamanca-Consejo Superior de Investigaciones Científicas, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1300439DOI Listing
August 2013